Alemtuzumab

Identification

Name
Alemtuzumab
Accession Number
DB00087 / 3A189DH42V
Groups
Campath
Description

Humanized monoclonal antibody precise to lymphocyte antigens. it is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) this is directed in opposition to the 21-28 kD cellular floor glycoprotein,CD52. The Campath-1H antibody is an IgG1 kappa with human variable framework and steady areas, and complementarity-figuring out regions from a murine (rat) monoclonal antibody (Campath-1G). Campath is produced in mammalian cellular (chinese language hamster ovary) suspension subculture in a medium containing neomycin.

Pharmacology

Pharmacodynamics

Campath is used to treat leukemia by exploiting antibody mediated lysis of CD52 presenting cells. The CD52 antigen is a cell surface protein found on essentially all B and T lymphocytes, a majority of monocytes, macrophages and most granulocytes. The CD52 antigen is not present on erythrocytes or hematopoetic stem cells. In leukemia there is an excess of B and T cells, so Campath permits selective reduction of lymphocyte populations.

Indication

Alemtuzumab (Campath) is a monoclonal antibody therapy used for treatment of B-cell chronic lymphocytic leukemia.

Action

Campath binds to the CD52 antigen present on most B and T lymphocytes. This binding leads to antibody-dependent lysis of leukemic cells.